Pharos iBio Co., Ltd. (KOSDAQ:388870)

South Korea flag South Korea · Delayed Price · Currency is KRW
9,870.00
-100.00 (-1.00%)
At close: Jan 23, 2026
22.15%
Market Cap127.78B
Revenue (ttm)n/a
Net Income (ttm)-9.82B
Shares Out12.95M
EPS (ttm)-759.07
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume218,536
Average Volume629,831
Open9,970.00
Previous Close9,970.00
Day's Range9,730.00 - 10,040.00
52-Week Range4,630.00 - 12,120.00
Beta-0.22
RSI48.04
Earnings DateMar 17, 2026

About Pharos iBio

Pharos iBio Co., Ltd. develops treatments for rare and refractory diseases using AI based drug development platform in South Korea. It develops PHI-101-AML that is in phase 1 clinical trial for the treatment of refractory/recurrent acute myelogenous leukemia (AML); PHI-101-OC that is in phase 1 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer; PHI-101-TNBC for the treatment of metastatic triple-negative breast cancer; PHI-101-RS, a radiation sensitizer; PHI-201, a K-Ras hub-protein inhibitor; PHI-301, a FAK hub-p... [Read more]

Industry Pharmaceutical Preparations
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 388870
Full Company Profile

Financial Performance

Financial Statements